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Abstract
Objective: To evaluate the effect of liraglutide on body weight and metabolic parameters asso-
ciated with cardiovascular risk in patient with or without  type 2 diabetes mellitus (DM).  
Methods: A descriptive, observational and analytical study was performed.  A review was con-
ducted on clinical records from patients seen in a cardiology private practice, who received 
liraglutide as a weight -reducing supplement, combined with prescription of several life style 
modiications as a  2000 kcal diet in men, or 1800 kcal diet in women and moderate daily aero-
bic exercise (at least 30 minutes, 5 times a week) during 3 months. Data from both, diabetic and 
non diabetic obese patients with body mass index (BMi) >30 kg/m2 and at least two failed weight 
lost attempts in previous twelve months were included. Thirty eight cases meeting these crite-
ria were selected.
Results: An average of 4.8 kg of weight lost at the end of three months were observed (p<0.001). 
Further beneits in several cardiovascular and/or metabolic risk factors such as: increased c-
HDL, decreased serum triglycerides and lowering of systolic blood pressure. Liraglutide showed 
an adequate safety proile, with only minor adverse reactions (nausea, dizziness, vomiting, 
diarrhea or constipation), which disappeared within the irst two weeks of treatment.
Conclusion: The effectiveness and security of liraglutide as an supplement for weight loss were 
demonstrated. Liraglutide also showed beneicial effects improving metabolic risk factor that 
leads to cardiovascular disease 
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Introduction
Overweight and obesity are 2 major health problems in our 
country, because of their prevalence, as well as the risk 
they generate in the development of metabolic and cardio-
vascular diseases (these constitute the leading cause of 
death in our country). According to the 2012 National Health 
and Nutrition Survey, 26 million adult Mexicans were over-
weight and 22 million were obese.1 Because of the multiple 
variables that play a role in the genesis of obesity, this condi-
tion creates a challenge for health professionals that can be 
difficult to overcome. Different drugs have been used as 
supplements in the handling of this disease; however, their 
use has been limited, and in some cases discontinued due to 
the adverse reactions generated, which in some cases has 
been fatal.2 
Glucagon-like peptide-1 (GLP-1) analogues are drugs de-
veloped for type 2 diabetes mellitus (DM) management.3,4 
Liraglutide is the second medication approved by the Food 
and Drug Administration (FDA).5 One of its advantages is lea-
ding to less hypoglycemia events compared with other oral 
antidiabetics.6-8 in addition to lower glucose levels, we are 
able to observe a decrease in body weight9 and an improve-
ment in insulin secretion in patients who receive this medi-
cation.10 Other studies have reported the decrease in car- 
diovascular risk factors.11 The mechanism of action of 
GLP-1’s incretin is well deined. It is produced in ileocolic C 
cells stimulating pancreatic secretion of insulin by interac-
tion with G protein.12,13 At a gastrointestinal level, liragluti-
de decreases acid gastric secretion and delayed gastric 
emptying by antral stimulation. Moreover, it inhibits propul-
sion of pylorus, and decreases motility in the digestive tract 
after food intake. it also induces early satiety through a me-
chanism in central nervous system wich is not yet speciied, 
which is thought to be AMPc stimulation.12,13 Furthermore, 
the possibility of the activation of neuronal receptors at the 
satiety center in the hypotalamus at the arcuate nucleus, 
has been suggested, as well as the inhibition of the solitary 
tract of the brain stem. Altogether, the diverse mechanisms 
mentioned favor a reduction in the caloric intake, which 
could result in weight loss.12,13
The objective of this study is to evaluate the effect of lira-
glutide on body weight and metabolic parameters associated 
with cardiovascular risk, in patients with or without type 2 DM.
Materials and methods
We conducted a descriptive, observational, analytical study, 
in which clinical iles of patients cared for from July 2011 to 
June 2012, in private cardiology practices in Monterrey, N. 
L., Mexico were reviewed. We selected those who were 
being prescribed liraglutide (from 0.6 to 1.8 mg every 24 
hours) in addition to follow a diet of 2000 kcal for men and 
1800 kcal for women, as well as the indication to perform 
moderate exercise for 30 minutes at least 5 times a week. 
We selected those who met the following criteria: having 
received liraglutide treatment for at least a period of 3 
months, having registered the following variables at the be-
ginning of the study and following 3 months of treatment: 
Body weight, body mass index (BMi, calculated using the 
following formula: weight in kilograms/square of body 
length in meters), blood pressure measured with an aneroid 
monitor, plasma glucose after fasting, lipid proile, glycos-
ylated hemoglobin and hepatic function tests measured 
with basic and routine laboratory techniques, body fat per-
centage obtained through impedanciometry using a Tanita® 
innerscan, mention of presence or absence of cardiovascu-
lar or digestive symptoms, and medication dosage prescri-
bed.
Administered liraglutide dosage was 0.6 mg a day during 
the irst week, which was gradually increased to 1.2 mg and 
up to 1.8 mg a day according to tolerance and requirement. 
in addition, we prescribed metformin to 14 of 15 diabetic 
patients and 13 of the 23 non-diabetic patients. 
For statistical analysis we utilized measures of central 
tendency and dispersion. in order to compare quantitative 
variables we used the Student’s T-test for both groups and 
analysis of variance when we analyzed more than 2. We 
used the statistical software SPSS® Statistics version 19.0. 
We consider a p < 0.05 as signiicant.
Results 
Thirty eigth cases met the inclusion criteria. There were 23 
(60%) males and 15 (40%) females, with an average age of 56 
± 10 years. Fifteen patients (40%) were under type 2 DM 
treatment. Coronary risk factor detected are listed in Table 1.
Average weight loss at the end of 3 months of treatment 
was 4.8 kg in 38 patients (p < 0.001), which was signiicant. 
These results, as well as the rest of the evaluated parame-
ters are shown in Table 2. 
We observed a signiicant average weigth loss of 4.2 Kg in 
diabetic patients and 5.2 in non-diabetic; futhermore, an 
improvement in several evaluated metabolic parameters 
(Tables 3 and 4). The analysis of variance displayed a non-
signiicant difference in the behavior between subgroups in 
weight reduction, BMi, body far percentage, serum triglyce-
rides, total cholesterol and c-LDL; differences found in sys-
tolic arterial pressure and c-LDL were signiicant. 
Six patients (16%) reported an adverse event of moderate 
intensity and relative frequency during the irst 2 weeks of 
treatment, particularly nausea, dizziness, vomiting, diarr-
hea and constipation; headaches and cramps occurred less fre-
quently. There were no reports of hypoglycemia episodes or 
hepatic enzyme alterations (TGO, TGP). Patients with heart 
diseases did not display data of cardiac decompensation. 
Table 1 Coronary risk factors present in participants. 
 N %
Smoking 7 18
Arterial hypertension 26 68
Dyslipidemia 21 55
Family history of coronary arterial 
disease
26 63
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Discussion 
Different studies and trials in which liraglutide has been admi-
nistered, have proven the usefulness of this medication in 
weight loss in obese patients with type 2 DM, as well as 
in patients without this condition. Weight losses between 7 to 9 
kg in 20 weeks have been reported, obtaining best results when 
using 3 mg of liraglutide a day.14-18 it has been proven superior 
when compared to placebo (2.8 kg) and orlistat (4.4 kg).11 
in this study, the obtained weight loss was slightly lo- 
wer than that reported, which can be attributed to a sma-
ller dose and a shorter duration of treatment.
An important parameter to evaluate weight loss is body 
fat percentage, because body fat at the abdominal level 
constitutes a risk factor for the development of metabolic 
syndrome. A publication reports a 1.2-1.9% decrease in body 
fat.18 in the present study we observed that at the end of 3 
months of treatment, body fat had lowered 2.5% on avera-
ge, which was slightly greater than that reported.
An improvement of different metabolic parameters when 
using liraglutide by itself, or in combination with other glu-
cose-lowering drugs has been reported. Previous studies 
showed reductions of up to 1.7% on glycosylated hemoglo-
bin, a decrease in triglycerides of 22 mg/dl, and in fasting 
plasma glucose of up to 43.2 mg/dl.11,14,15 
in this study, we are able to see that glycosylated hemog-
lobin and triglycerides values decreased even if it was to a 
smaller degree than that reported.
Table 2 Average (Avg), standard deviation (SD) and difference in the evaluated parameters in all patients, before and after 
the administration of the drug (n=38).
Before After
 Avg SD Avg SD Difference p
Weight (kg) 98.7 6.0 93.8 5.7 - 4.8 < 0.001
Body fat (%) 35.6 2.4 33.1 6.4 - 2.5 < 0.001
Body mass index (BMi) 33.0 2.0 31.4 31.8 - 1.6 < 0.001
Systolic blood pressure (mmHg) 137.7 7.5 132.2 0.4 - 5.6 < 0.001
Glucose (mg/dl) 124.1 41.4 117.1 20.0 - 6.9 NS
HbA1c* 8.4 0.6 7.9 3.2 - 0.5 NS
Total cholesterol (mg/dl) 211.5 14.4 208.7 9.3 - 2.8 NS
c-HDL (mg/dl) 35.4 2.7 38.3 17.9 2.9 < 0.001
c-LDL (mg/dl) 128.7 12.1 127.8 2.5 - 0.9 NS
Triglycerides (mg/dl) 178.5 19.7 169.1 1.9 - 9.4 < 0.001
* Glycosylated hemoglobin was only measured in diabetic patients. 
NS: non-signiicant.
Table 3 Average (Avg), standard deviation (SD) and difference between the evaluated parameters in patients with type 2 
diabetes mellitus, before and after the administration of the drug (n=15).
Before After
 Avg SD Avg SD Difference p
Weight (kg) 96.8 7.0 92.6 6.6 - 4.2 < 0.025
Body fat (%) 34.9 2.7 33.6 2.7 - 1.4 < 0.001
Body mass index (BMi) 32.4 2.4 30.9 2.2 - 1.4 NS
Systolic blood pressure (mmHg) 134.4 7.6 131.6 6.5 - 2.8 NS
Glucose (mg/dl) 172.7 17.4 154.1 15.1 - 18.6 NS
HbA1c 8.4 0.6 7.9 0.4 - 0.5 NS
Total cholesterol (mg/dl) 221.3 11.9 228.7 11.9 7.4 NS
c-HDL (mg/dl) 35.3 2.3 37.6 2.2 2.3 < 0.001
c-LDL (mg/dl) 117.7 9.1 126.3 10.7 8.5 < 0.025
Triglycerides (mg/dl) 188.9 17.4 175.3 18.9 - 13.7 NS
NS: non-signiicant.
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A study had shown the reduction of systolic blood pressure 
of 6.1 mmHg on average.11
in our study the reductions in blood pressure were slightly 
superior to those reported in the literature.
Diverse side effects have been reported. Over 10% of the 
patients have presented gastrointestinal discomfort (nau-
sea, vomiting and diarrhea); consequently, dose should be 
titrated in order to avoid the main adverse gastrointestinal 
effects.19 From 1% to 10% of patients developed upper tract 
respiratory infections, headaches and high levels of anti-li-
raglutide antibodies.19,20 it has not been possible to demons-
trate the relationship between liraglutide and pancreatitis, 
thyroid C-cell hyperplasia, and thyroid papillary carcino-
ma.21,22
in our study, 16% of the patients showed minor adverse 
gastrointestinal reactions (i.e. nausea and diarrhea), which 
disappeared within the irst two weeks of treatment. There 
were no hypoglycemia or pancreatitis cases, which could be 
related to the selection of patients or the sample size.
The study has several limitations: is a retrospective, des-
criptive, and non-randomized design, with a small sample 
size, as well as a short time frame. 
Conclusions
The effectiveness of liraglutide as supplement for weight 
loss was demonstrated in patients with a BMi greater than 
30 kg/m2, with or without type 2 DM, with at least 2 failed 
attempts at losing weight in the last 12 months, successfully 
losing an average weight of 4.8 kg in 3 months of treatment.
in the case of type 2 DM patients, we obtained an impro-
vement in glycosylated hemoglobin, fasting glucose, blood 
pressure and triglycerides, which theoretically shows a be-
neicial effect improving metabolic risk factors that lead to 
cardiovascular disease. The drug’s safety proile was ade-
quate, with minimal adverse effects.
it is important to note that the present study was not a 
controlled clinical study. results are based on real life priva-
te ofice patients. 
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